報價延遲最少15分鐘:2026/05/11 00:40 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
121.29 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.71/-5.62
|
|
企業價值
1.62B
|
| 資產負債 |
|
每股賬面淨值
1.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment. |
